• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cue Health Inc. (Amendment)

    2/14/23 6:36:21 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HLTH alert in real time by email
    SC 13G/A 1 tm236013d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G
     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    CUE HEALTH INC.
    (Name of Issuer)

     

    Common Stock, par value $0.00001 Per Share
    (Title of Class of Securities)

     

    229790100
    (CUSIP Number)

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 229790100   13G   Page 2 of 8 Pages

     

    1

    Names of Reporting Persons
    I.R.S. Identification Number (Entity Only)

     

    Robert A. Day

    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)   ¨
    (b)   ¨
    3 SEC USE ONLY
    4  Citizenship or Place of Organization: United States

    Number Of
    Shares

    Beneficially

    Owned by

    Each Reporting Person With:

    5 Sole Voting Power:  1,170,762
    6 Shared Voting Power:  2,793,052
    7 Sole Dispositive Power:  1,170,762
    8 Shared Dispositive Power:  8,424,586

    9

    Aggregate Amount Beneficially Owned By Each Reporting Person:

     

    9,595,348

    10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11

    Percent of Class Represented by Amount in Row (9):

     

    6.4%

    12 Type of Reporting Person (See Instructions): IN

     

     

     

     

    CUSIP No. 229790100   13G   Page 3 of 8 Pages

     

    1

    Names of Reporting Persons

     

    Oakmont Corporation

    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)   ¨
    (b)   ¨
    3 SEC USE ONLY
    4  Citizenship or Place of Organization: California

    Number Of
    Shares

    Beneficially

    Owned by

    Each Reporting Person With:

    5 Sole Voting Power:  1,170,762
    6 Shared Voting Power:  2,793,052
    7 Sole Dispositive Power:  1,170,762
    8 Shared Dispositive Power:  8,424,586

    9

    Aggregate Amount Beneficially Owned By Each Reporting Person:

     

    9,595,348

    10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11

    Percent of Class Represented by Amount in Row (9):

     

    6.4%

    12 Type of Reporting Person (See Instructions): CO

     

     

     

     

    CUSIP No. 229790100   13G   Page 4 of 8 Pages

     

    1

    Names of Reporting Persons

    I.R.S. Identification Number (Entity Only)

     

    Kelly Day

    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)   ¨
    (b)   ¨
    3 SEC USE ONLY
    4  Citizenship or Place of Organization: United States

    Number Of
    Shares

    Beneficially

    Owned by

    Each Reporting Person With:

    5 Sole Voting Power:  5,631,534
    6 Shared Voting Power:  2,793,052
    7 Sole Dispositive Power:  0
    8 Shared Dispositive Power:  2,793,052

    9

    Aggregate Amount Beneficially Owned By Each Reporting Person:

     

    8,424,586

    10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11

    Percent of Class Represented by Amount in Row (9):

     

    5.6%

    12 Type of Reporting Person (See Instructions): IN

     

     

     

     

    CUSIP No. 229790100   13G   Page 5 of 8 Pages

     

    Item 1(a).Name of Issuer:

     

      Cue Health Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

      4980 Carroll Canyon Road, Suite 100
    San Diego, CA 92121

     

    Item 2(a).Name of Person Filing:

     

      Robert A. Day
      Oakmont Corporation
      Kelly Day
       
      (Each a “Reporting Person,” and collectively, the “Reporting Persons”).

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

      The principal business office for all Reporting Persons filing is:
       
      865 South Figueroa Street, Suite 700
      Los Angeles, CA 90017

     

    Item 2(c).Citizenship:

     

      See Item 4 of each cover page.

     

    Item 2(d).Title of Class of Securities:

     

     Common Stock, par value $0.00001 per share (the “Shares”)

     

    Item 2(e).CUSIP Number:

     

     229790100

     

    Item 3.If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      Not Applicable

     

    Item 4.Ownership:

     

      Oakmont Corporation (i) has been granted authority to manage the disposition of Shares owned by Cove Investors II, LLC (“Cove II”), (ii) is the Manager of, and controls the voting and disposition of Shares owned by Cove Investors III, LLC (“Cove III”), and (iii) is the investment advisor to Kelly Day. Kelly Day, as an owner of Cove II, has rights to control the voting (but not the disposition) of Shares owned by Cove II. In these capacities, Oakmont Corporation holds sole voting and investment power over 1,170,762 Shares held directly by Cove III, shared investment power with the owners of Cove II over 5,631,534 Shares held directly by Cove II, and shared voting and investment power with Kelly Day over 2,793,052 Shares held by Kelly Day as Trustee of the Kelly Day 2021 Annuity Trust. Kelly Day has sole voting power over 5,631,534 Shares held directly by Cove II. Robert A. Day is the sole owner of Oakmont Corporation.  
       
      As a result of these relationships, each of Oakmont Corporation, Robert A. Day and Kelly Day may be deemed to have or share beneficial ownership of the Shares held directly by Cove II, Cove III and Kelly Day. Each of the Reporting Persons disclaims beneficial ownership of such securities not directly owned by such Reporting Person.

     

     

     

     

    CUSIP No. 229790100   13G   Page 6 of 8 Pages

     

      (a) Amount beneficially owned:  See Item 9 of each cover page.
      (b) Percent of class: See Item 11 of each cover page. Calculated using 149,432,436 Shares outstanding as of November 1, 2022, as reported by the Issuer in its Quarterly Report on Form 10-Q filed by the Issuer on November 9, 2022.
      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote: See Item 5 of each cover page.
        (ii) Shared power to vote or to direct the vote: See Item 6 of each cover page.
        (iii) Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.
        (iv) Shared power to dispose or to direct the disposition of: See Item 8 of each cover page.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

      Not Applicable

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

      Not Applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

      Not Applicable

     

    Item 8.Identification and Classification of Members of the Group:

     

      Not Applicable

     

    Item 9.Notice of Dissolution of Group:

     

      Not Applicable

     

    Item 10.Certifications:

     

      Not Applicable

     

     

     

     

    CUSIP No. 229790100   13G   Page 7 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023  
      Robert Day
       
      /s/ Robert Miller
      Robert Miller, as Attorney-in-Fact for Robert Day
       
      Oakmont Corporation
       
      By:   /s/ Robert Miller
        Robert Miller, Managing Director
       
      Kelly Day
       
      /s/ Kelly Day
      Kelly Day

     

     

     

     

    CUSIP No. 229790100   13G   Page 8 of 8 Pages

     

    EXHIBIT INDEX

     

    Exhibit
    Number
    Title
       
    99.1 Joint Filing Agreement

     

     

     

     

    EXHIBIT 99.1

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, par value $0.00001 per share, of Cue Health Inc. (this “Agreement”), is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated: February 14, 2022  
      Robert Day
       
      /s/ Robert Miller
      Robert Miller, as Attorney-in-Fact for Robert Day
       
      Oakmont Corporation
       
      By:   /s/ Robert Miller
        Robert Miller, Managing Director
       
      Kelly Day
       
      /s/ Kelly Day
      Kelly Day

     

     

     

    Get the next $HLTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLTH

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Health to Pursue Wind Down of the Business

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

      5/28/24 4:31:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

      Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

      5/13/24 8:30:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

      For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

      6/6/23 3:04:14 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    SEC Filings

    See more
    • Cue Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/28/24 5:02:54 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:20:43 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Cue Health Inc.

      NT 10-Q - Cue Health Inc. (0001628945) (Filer)

      5/16/24 4:17:26 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Financials

    Live finance-specific insights

    See more
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Reports Fourth Quarter 2023 Financial Results

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

      3/13/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

      2/28/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Cue Health Announces Strategic Actions to Position Company for Next Stage

      Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

      3/20/24 5:21:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Rishi Reddy to Board of Directors

      Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

      2/16/24 5:00:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

      Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D. have joined its Board of Directors. Cue Health's Board now consists of seven directors, five of whom are independent. "On behalf of the management team and Board, I'm pleased to welcome both Josh and Sachin to the Cue team. We are excited to have vast knowledge of health plans and payors as well as the perspective of a medical doctor on Cue's Board as we continue to pursue our vision of making healthcare more convenient, accessible, and timely by placing diagnostic information at the center of care," said Ayub

      11/17/22 4:15:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      5/17/24 3:21:32 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

      SC 13D/A - Cue Health Inc. (0001628945) (Subject)

      2/21/24 5:00:19 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cue Health Inc. (Amendment)

      SC 13G/A - Cue Health Inc. (0001628945) (Subject)

      2/14/24 5:09:58 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Javed Aasim covered exercise/tax liability with 13,327 shares, decreasing direct ownership by 1% to 998,004 units (SEC Form 4) (Amendment)

      4/A - Cue Health Inc. (0001628945) (Issuer)

      5/21/24 6:29:25 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sever Clint covered exercise/tax liability with 20,456 shares, decreasing direct ownership by 0.46% to 4,379,914 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/27/24 7:29:01 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pollard Randall E. covered exercise/tax liability with 7,304 shares, decreasing direct ownership by 1% to 503,202 units (SEC Form 4)

      4 - Cue Health Inc. (0001628945) (Issuer)

      3/7/24 8:45:08 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cue Health downgraded by BTIG Research

      BTIG Research downgraded Cue Health from Buy to Neutral

      3/14/24 7:38:37 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • BTIG Research initiated coverage on Cue Health with a new price target

      BTIG Research initiated coverage of Cue Health with a rating of Buy and set a new price target of $18.00

      10/19/21 9:45:18 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Cue Health with a new price target

      Morgan Stanley initiated coverage of Cue Health with a rating of Equal-Weight and set a new price target of $12.00

      10/19/21 8:30:49 AM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials